Edwards Lifesciences Corp (EW) - Total Liabilities
Based on the latest financial reports, Edwards Lifesciences Corp (EW) has total liabilities worth $3.14 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore EW strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Edwards Lifesciences Corp - Total Liabilities Trend (1999–2025)
This chart illustrates how Edwards Lifesciences Corp's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Edwards Lifesciences Corp total assets.
Edwards Lifesciences Corp Competitors by Total Liabilities
The table below lists competitors of Edwards Lifesciences Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NATWEST GROUP SP.ADR/2
F:RYS
|
Germany | €705.97 Billion |
|
Sandvik AB
ST:SAND
|
Sweden | Skr81.89 Billion |
|
Roche Holding AG
SW:RO
|
Switzerland | CHF61.48 Billion |
|
Nebius Group N.V.
NASDAQ:NBIS
|
USA | $17.62 Billion |
|
Hindustan Unilever Limited
NSE:HINDUNILVR
|
India | Rs328.72 Billion |
|
Suzhou Dongshan Precision Manufacturing Co Ltd
SHE:002384
|
China | CN¥40.15 Billion |
|
Becton Dickinson and Company
NYSE:BDX
|
USA | $26.31 Billion |
|
Nasdaq Inc
NASDAQ:NDAQ
|
USA | $18.82 Billion |
Liability Composition Analysis (1999–2025)
This chart breaks down Edwards Lifesciences Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See EW equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Edwards Lifesciences Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Edwards Lifesciences Corp (1999–2025)
The table below shows the annual total liabilities of Edwards Lifesciences Corp from 1999 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.36 Billion | +12.27% |
| 2024-12-31 | $2.99 Billion | +13.19% |
| 2023-12-31 | $2.64 Billion | +6.36% |
| 2022-12-31 | $2.49 Billion | -6.78% |
| 2021-12-31 | $2.67 Billion | +0.15% |
| 2020-12-31 | $2.66 Billion | +13.80% |
| 2019-12-31 | $2.34 Billion | +7.17% |
| 2018-12-31 | $2.18 Billion | -19.19% |
| 2017-12-31 | $2.70 Billion | +42.88% |
| 2016-12-31 | $1.89 Billion | +21.51% |
| 2015-12-31 | $1.56 Billion | +16.75% |
| 2014-12-31 | $1.33 Billion | +14.36% |
| 2013-12-31 | $1.17 Billion | +57.03% |
| 2012-12-31 | $742.20 Million | +15.50% |
| 2011-12-31 | $642.60 Million | +40.00% |
| 2010-12-31 | $459.00 Million | +0.31% |
| 2009-12-31 | $457.60 Million | -12.24% |
| 2008-12-31 | $521.40 Million | +2.22% |
| 2007-12-31 | $510.10 Million | +2.55% |
| 2006-12-31 | $497.40 Million | -7.74% |
| 2005-12-31 | $539.10 Million | +11.25% |
| 2004-12-31 | $484.60 Million | +3.92% |
| 2003-12-31 | $466.30 Million | -0.53% |
| 2002-12-31 | $468.80 Million | -8.79% |
| 2001-12-31 | $514.00 Million | -20.68% |
| 2000-12-31 | $648.00 Million | +204.23% |
| 1999-12-31 | $213.00 Million | -- |
About Edwards Lifesciences Corp
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to t… Read more